Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The foot-and-mouth disease virus capsid protein VP3 is a structural component of the viral icosahedral capsid that plays dual roles in viral assembly and immune evasion. As part of the pseudo-T=3 symmetric capsid structure alongside VP0 and VP1, VP3 contributes to the overall architecture and stability of the virion. Beyond its structural function, VP3 acts as a potent antagonist of host innate immunity by suppressing interferon signaling pathways through interactions with key host proteins including JAK1 and VISA, thereby facilitating viral replication and persistence. The protein is relatively conserved across FMDV serotypes, with specific residues such as arginine 56 being critical for both virulence and receptor binding. While VP3 is not currently a therapeutic drug target, understanding its mechanisms of immune evasion and structural functions remains important for developing strategies to control foot-and-mouth disease in livestock populations.
Not applicable - VP3 is not targeted by drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Foot-and-mouth disease virus capsid protein VP3 (VP3).